Daniil Gataulin
Stock Analyst at Chardan Capital
(3.99)
# 654
Out of 4,412 analysts
28
Total ratings
33.33%
Success rate
24.47%
Average return
Main Sectors:
Top Industries:
8 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OCGN Ocugen | Maintains: Buy | $4 → $5 | $1.28 | +290.63% | 4 | Apr 22, 2024 | |
| OCS Oculis Holding AG | Maintains: Buy | n/a | $12.02 | - | 2 | Mar 19, 2024 | |
| ADVM Adverum Biotechnologies | Reiterates: Buy | $40 | $9.19 | +335.26% | 4 | Mar 19, 2024 | |
| PPBT Purple Biotech | Maintains: Buy | $11 | $0.49 | +2,144.90% | 1 | Mar 7, 2024 | |
| RGNX REGENXBIO | Maintains: Buy | $52 | $16.19 | +221.19% | 6 | Mar 7, 2024 | |
| OTLK Outlook Therapeutics | Upgrades: Buy | $60 | $8.43 | +611.74% | 5 | Feb 15, 2024 | |
| EYPT EyePoint Pharmaceuticals | Reiterates: Buy | $22 | $16.75 | +31.34% | 4 | Aug 3, 2023 | |
| KOD Kodiak Sciences | Downgrades: Neutral | n/a | $3.28 | - | 2 | Jul 25, 2023 |
Ocugen
Apr 22, 2024
Maintains: Buy
Price Target: $4 → $5
Current: $1.28
Upside: +290.63%
Oculis Holding AG
Mar 19, 2024
Maintains: Buy
Price Target: n/a
Current: $12.02
Upside: -
Adverum Biotechnologies
Mar 19, 2024
Reiterates: Buy
Price Target: $40
Current: $9.19
Upside: +335.26%
Purple Biotech
Mar 7, 2024
Maintains: Buy
Price Target: $11
Current: $0.49
Upside: +2,144.90%
REGENXBIO
Mar 7, 2024
Maintains: Buy
Price Target: $52
Current: $16.19
Upside: +221.19%
Outlook Therapeutics
Feb 15, 2024
Upgrades: Buy
Price Target: $60
Current: $8.43
Upside: +611.74%
EyePoint Pharmaceuticals
Aug 3, 2023
Reiterates: Buy
Price Target: $22
Current: $16.75
Upside: +31.34%
Kodiak Sciences
Jul 25, 2023
Downgrades: Neutral
Price Target: n/a
Current: $3.28
Upside: -